C4 治疗学认为利息下降很短,而机构投资者则增加了癌症治疗公司的股权。 C4 Therapeutics sees short interest drop, while institutional investors increase stakes in the cancer treatment firm.

C4 Therapeutics的空头股数在1月份下跌了20.3%，截至1月31日，有740万股被卖空。 C4 Therapeutics saw a 20.3% drop in short interest in January, with 7.4 million shares shorted as of January 31. 该公司的股票交易额为3.18美元,其主要产品FCT7455正处于癌症治疗临床试验第1/2阶段。 The company's stock trades at $3.18, and its lead product, CFT7455, is in Phase 1/2 clinical trials for cancer treatments. 一些机构投资者增加了他们的利害关系,分析师从持股到买入的评级不一,协商一致的目标价格为11.60美元。 Several institutional investors increased their stakes, and analysts have given ratings ranging from hold to buy, with a consensus target price of $11.60.